FDA has approved Clariscan, macrocyclic – gadolinium based magnetic resonance imaging contrast agent. Clariscan is a gadolinium based contrast agent which is used with MRI in brain, spine and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier.
The new contrast agent Clariscan has been approved in 55 countries and more than four million patients doses shipped in those countries. This contrast agent is the latest in growing imaging agents available in the US from GE.
Clariscan is manufactured in Norway using a proprietary manufacturing process. Clariscan is a paramagnetic molecule that develops a magnetic moment when placed in a magnetic field. It increases the relaxation rate of water protons and leads to an increase in signal intensity of tissues. The product is available in single dose vials of 10, 15 and 20ml.
About us and this blog
We are a teleradiology service provider with a focus on helping our customers to repor their radiology studies. This blog brings you information about latest happenings in the medical radiology technology and practices.
Request a free quote
We offer professional teleradiology services that help hospitals and imaging centers to report their radiology cases on time with atmost quality.
Subscribe to our newsletter!
More from our blog
See all posts
Recent Posts
- Understanding the Challenges of Teleradiology in India January 19, 2023
- Benefits of Teleradiology for Medical Practices January 16, 2023
- Digital Transformation of Radiology January 2, 2023